Expand HELP Menu
HELP MENU

HELP Latest Press Releases

-- October 8, 2026 --

Helus Pharma to Host Investor Presentation on October 21, 2026 Globe Newswire 7:30 AM

-- October 1, 2026 --

Helus Pharma Announces Completion of Legal Name Change Globe Newswire 7:30 AM

-- September 22, 2026 --

Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change Globe Newswire 5:00 PM

-- September 21, 2026 --

Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit Globe Newswire 5:15 PM
Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026 Globe Newswire 7:30 AM

-- September 10, 2026 --

Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York Globe Newswire 7:30 AM

-- September 9, 2026 --

Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York Globe Newswire 7:30 AM

-- September 3, 2026 --

Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York Globe Newswire 7:30 AM

-- August 18, 2026 --

Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board Globe Newswire 7:30 AM

-- August 14, 2026 --

Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights Globe Newswire 7:28 AM

-- August 10, 2026 --

Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston Globe Newswire 12:00 PM

-- August 5, 2026 --

A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout Globe Newswire 10:25 AM

-- August 3, 2026 --

Helus Pharma Appoints Michael Halstead as Chief Executive Officer Globe Newswire 7:40 AM

-- July 21, 2026 --

Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule PRNewswire 10:55 AM
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule Globe Newswire 7:50 AM

-- June 30, 2026 --

Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity Globe Newswire 9:00 AM

-- June 29, 2026 --

Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results Globe Newswire 7:40 AM

-- June 26, 2026 --

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year PRNewswire 9:30 AM

-- June 25, 2026 --

Helus Pharma Announces Closing of US$50 Million Underwritten Offering Globe Newswire 9:27 AM

-- June 24, 2026 --

Helus Pharma Announces US$50 Million Underwritten Offering Globe Newswire 6:01 AM
Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress Globe Newswire 6:00 AM

-- June 11, 2026 --

Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference Globe Newswire 7:30 AM

-- June 1, 2026 --

Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York Globe Newswire 7:30 AM
Market Data Delayed 15 Minutes